SINGAPORE, March 31, 2025 /PRNewswire/ -- The wait is almost over! Ragnarok Landverse: Genesis, the Web3-enhanced version of the legendary MMORPG Ragnarok Online, is officially launching its Grand Launch on March 29, 2025, at 14:00 UTC+7. Developed in partnership between GRAVITY, MAXION, SKY MAVIS, and ZENTRY, this highly anticipated release promises to blend classic Ragnarok nostalgia with blockchain technology, offering players true digital ownership of in-game assets.
A New Era of Ragnarok Begins
Ragnarok Landverse: Genesis aims to bring the beloved world of Ragnarok Online into the Web3 ecosystem, providing players with exciting opportunities to earn, trade, and collect valuable in-game assets through blockchain integration. This launch represents a major milestone in decentralized gaming, where players can fully engage in a Play-to-Earn (P2E) system while enjoying the familiar mechanics of the classic MMORPG.
Core Features of Ragnarok Landverse: Genesis
With the Grand Launch, players can expect a host of exciting features that enhance both the traditional gameplay experience and the Web3 ecosystem:
1. Episode 4.0 & Classic Ragnarok Experience
2. Web3 & Blockchain Integration
3. Automated System Mode – Play While AFK!
4. War of Emperium – Epic Guild Battles
5. Exclusive Events and Rewards
Pre-Launch Preparations – How to Join the Adventure
With Ragnarok Landverse: Genesis entering its OBT phase, players can prepare by taking the following steps:
Join the Adventure – The Next Chapter Awaits!
Don't miss out on the Grand Launch of Ragnarok Landverse: Genesis! Whether you're a veteran Ragnarok Online player or a newcomer looking for an innovative MMORPG experience, this is your chance to be part of a groundbreaking adventure.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Ragnarok Landverse: Genesis Grand Launch Set for March 29, 2025
BEIJING, April 4, 2025 /PRNewswire/ -- Recently, Beijing Tsingke Biotech Co., Ltd. officially announced the appointment of Dr. Yaning Wang, a former senior expert at the FDA, as the company's Chief Scientific Advisor in the field of small nucleic acid. This collaboration injects strong momentum into Tsingke's growth in small nucleic acid drugs raw materials, marking a significant enhancement in the company's technical capabilities, regulatory compliance, and quality control.
Dr. Yaning Wang's Industry Experience and Contributions
As the global small nucleic acid drugs market rapidly expands, driven by growing demand for precise treatments targeting genetic disorders, rare diseases, and cancer. The high specificity of small nucleic acid drugs makes them particularly promising for rare diseases caused by single-gene mutations. However, this progress also comes with technical hurdles and increasingly stringent regulatory requirements. Amidst the surging market and growing regulatory challenges, Dr. Yaning Wang joins Tsingke at this pivotal moment to strengthen our capabilities on RNA technologies. His expertise will help Tsingke drive the development of high-quality, customized small nucleic acid solutions while accelerating innovation in nucleic acid drug development.
Dr. Yaning Wang has extensive experience and outstanding achievements in the pharmaceutical industry. He obtained his Bachelor's degree in Pharmacy from Peking University in 1996, followed by a Master's degree in Biochemistry from the National Anti-Doping Center in 1999. In 2003, he earned a dual degree-a Ph.D. in Pharmacy and a Master's in Statistics-from the University of Florida.
During his tenure at the U.S. Food and Drug Administration (FDA), Dr. Wang held several key positions, ultimately serving as Director of the Division of Quantitative Pharmacology in the Office of Clinical Pharmacology. He played a leading role in the approval of multiple new drugs, ensuring their safety and efficacy, and made significant contributions to the advancement of global drug regulation.
"We are thrilled to welcome Dr. Yaning Wang to Tsingke. His extensive expertise and remarkable contributions to the pharmaceutical industry will undoubtedly strengthen Tsingke position in the rapidly evolving field of small nucleic acids. Through its collaboration with Dr. Wang, Tsingke will integrate the latest global regulatory standards and compliance guidelines, strengthening regulatory management capabilities to ensure its products meet the highest quality and safety standards in complex market environments," said Shijin Ma, President of Tsingke.
About Tsingke
Tsingke leads DNA/RNA synthesis with a full-chain platform offering gene synthesis, oligo modification, antibodies, proteins, gene regulation, and detection. Backed by a 12,000㎡ R&D facility, a 100,000-class clean workshop, and 300+ IP rights, Tsingke delivers high-quality solutions trusted by 300,000+ customers worldwide.
In small nucleic acid drug development, Tsingke drives innovation in synthesis, modification, delivery, and scale-up. With an end-to-end service model-from sequence design to validation-the company supports both research and GMP-grade production through its large-scale oligo API platform. By ensuring drug safety and delivery efficiency, Tsingke provides global researchers with tailored solutions and expert support.
For more information on Tsingke, please visit https://www.tsingke.com/ or connect with us on LinkedIn at https://www.linkedin.com/company/tsingke/.
Beijing Tsingke Biotech Co., Ltd.
market@tsingke.com.cn
https://www.tsingke.com/
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Ex-FDA Expert Dr. Yaning Wang Joins Tsingke to Drive Small Nucleic Acid Drug Innovation
